Do analysts recommend TLPH or SPRO?

Talphera presently has a consensus price target of $3.00, indicating a potential upside of 254.27%. Given Talphera's stronger consensus rating and higher probable upside, analysts plainly believe Talphera is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer TLPH or PLX?

In the previous week, Talphera had 6 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 7 mentions for Talphera and 1 mentions for Protalix BioTherapeutics. Talphera's average media sentiment score of 0.90 beat Protalix BioTherapeutics' score of 0.00 indicating that Talphera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talphera 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TLPH or MOLN more profitable?

Molecular Partners' return on equity of -66.62% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Talphera N/A -92.98% -53.22% Molecular Partners N/A -66.62% -54.85%

Do analysts recommend TLPH or ORMP?

Talphera presently has a consensus price target of $3.00, indicating a potential upside of 254.27%. Given Talphera's stronger consensus rating and higher possible upside, equities analysts plainly believe Talphera is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is TLPH or ORMP more profitable?

Oramed Pharmaceuticals' return on equity of -5.37% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Talphera N/A -92.98% -53.22% Oramed Pharmaceuticals N/A -5.37% -4.83%

Does the media refer more to TLPH or ORMP?

In the previous week, Talphera had 6 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 7 mentions for Talphera and 1 mentions for Oramed Pharmaceuticals. Talphera's average media sentiment score of 0.90 beat Oramed Pharmaceuticals' score of 0.00 indicating that Talphera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talphera 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oramed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend OGI or TLPH?

Talphera has a consensus target price of $3.00, indicating a potential upside of 254.27%. Given Talphera's higher possible upside, analysts plainly believe Talphera is more favorable than Organigram Global. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram Global 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Talphera 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Talphera (TLPH) Competitors

$0.85 +0.07 (+9.26%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$0.85 +0.01 (+0.61%)

As of 06/8/2026 07:59 PM Eastern

Compare

TLPH vs. SPRO, PLX, MOLN, ORMP, and OGI

Should you buy Talphera stock or one of its competitors? MarketBeat compares Talphera with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Talphera include Spero Therapeutics (SPRO), Protalix BioTherapeutics (PLX), Molecular Partners (MOLN), Oramed Pharmaceuticals (ORMP), and Organigram Global (OGI). These companies are all part of the "pharmaceutical products" industry.

How does Talphera compare to Spero Therapeutics?

Talphera (NASDAQ:TLPH) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Talphera has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

In the previous week, Talphera had 7 more articles in the media than Spero Therapeutics. MarketBeat recorded 7 mentions for Talphera and 0 mentions for Spero Therapeutics. Talphera's average media sentiment score of 0.90 beat Spero Therapeutics' score of 0.00 indicating that Talphera is being referred to more favorably in the media.

Company	Overall Sentiment
Talphera	Positive
Spero Therapeutics	Neutral

37.7% of Talphera shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 3.5% of Talphera shares are owned by insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Spero Therapeutics has a net margin of 24.90% compared to Talphera's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-92.98%	-53.22%
Spero Therapeutics	24.90%	35.58%	24.95%

Talphera presently has a consensus price target of $3.00, indicating a potential upside of 254.27%. Given Talphera's stronger consensus rating and higher probable upside, analysts plainly believe Talphera is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Spero Therapeutics has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	1,464.96	-$14.29M	-$0.31	N/A
Spero Therapeutics	$66.80M	2.37	$8.57M	$0.24	11.42

Summary

Talphera and Spero Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Talphera compare to Protalix BioTherapeutics?

Talphera (NASDAQ:TLPH) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

Talphera has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market.

Talphera has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-92.98%	-53.22%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Protalix BioTherapeutics has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	1,464.96	-$14.29M	-$0.31	N/A
Protalix BioTherapeutics	$76.38M	2.07	$8.31M	$0.18	10.89

In the previous week, Talphera had 6 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 7 mentions for Talphera and 1 mentions for Protalix BioTherapeutics. Talphera's average media sentiment score of 0.90 beat Protalix BioTherapeutics' score of 0.00 indicating that Talphera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Talphera	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Talphera currently has a consensus target price of $3.00, indicating a potential upside of 254.27%. Protalix BioTherapeutics has a consensus target price of $12.00, indicating a potential upside of 512.24%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

37.7% of Talphera shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 3.5% of Talphera shares are owned by company insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Talphera and Protalix BioTherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Talphera compare to Molecular Partners?

Talphera (NASDAQ:TLPH) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Talphera has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

In the previous week, Talphera had 7 more articles in the media than Molecular Partners. MarketBeat recorded 7 mentions for Talphera and 0 mentions for Molecular Partners. Talphera's average media sentiment score of 0.90 beat Molecular Partners' score of 0.00 indicating that Talphera is being referred to more favorably in the media.

Company	Overall Sentiment
Talphera	Positive
Molecular Partners	Neutral

Talphera presently has a consensus price target of $3.00, indicating a potential upside of 254.27%. Molecular Partners has a consensus price target of $8.38, indicating a potential upside of 100.36%. Given Talphera's stronger consensus rating and higher possible upside, equities analysts clearly believe Talphera is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Talphera has higher earnings, but lower revenue than Molecular Partners. Talphera is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	1,464.96	-$14.29M	-$0.31	N/A
Molecular Partners	$5.65M	29.87	-$74.41M	-$1.94	N/A

37.7% of Talphera shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 3.5% of Talphera shares are owned by insiders. Comparatively, 5.9% of Molecular Partners shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Molecular Partners' return on equity of -66.62% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-92.98%	-53.22%
Molecular Partners	N/A	-66.62%	-54.85%

Summary

Talphera beats Molecular Partners on 9 of the 14 factors compared between the two stocks.

How does Talphera compare to Oramed Pharmaceuticals?

Talphera (NASDAQ:TLPH) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

In the previous week, Talphera had 6 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 7 mentions for Talphera and 1 mentions for Oramed Pharmaceuticals. Talphera's average media sentiment score of 0.90 beat Oramed Pharmaceuticals' score of 0.00 indicating that Talphera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Talphera	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oramed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oramed Pharmaceuticals has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	1,464.96	-$14.29M	-$0.31	N/A
Oramed Pharmaceuticals	$2M	74.49	$64.05M	$2.59	1.41

Talphera has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

37.7% of Talphera shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 3.5% of Talphera shares are owned by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Oramed Pharmaceuticals' return on equity of -5.37% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-92.98%	-53.22%
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%

Talphera presently has a consensus price target of $3.00, indicating a potential upside of 254.27%. Given Talphera's stronger consensus rating and higher possible upside, equities analysts plainly believe Talphera is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Oramed Pharmaceuticals beats Talphera on 8 of the 15 factors compared between the two stocks.

How does Talphera compare to Organigram Global?

Organigram Global (NASDAQ:OGI) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

34.6% of Organigram Global shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 0.1% of Organigram Global shares are held by insiders. Comparatively, 3.5% of Talphera shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Talphera has lower revenue, but higher earnings than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram Global	$185.07M	0.81	-$17.70M	-$0.13	N/A
Talphera	$30K	1,464.96	-$14.29M	-$0.31	N/A

Organigram Global has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Talphera has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Talphera has a net margin of 0.00% compared to Organigram Global's net margin of -9.22%. Organigram Global's return on equity of -13.41% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram Global	-9.22%	-13.41%	-9.09%
Talphera	N/A	-92.98%	-53.22%

Talphera has a consensus target price of $3.00, indicating a potential upside of 254.27%. Given Talphera's higher possible upside, analysts plainly believe Talphera is more favorable than Organigram Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram Global	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Talphera	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Talphera had 7 more articles in the media than Organigram Global. MarketBeat recorded 7 mentions for Talphera and 0 mentions for Organigram Global. Talphera's average media sentiment score of 0.90 beat Organigram Global's score of 0.00 indicating that Talphera is being referred to more favorably in the news media.

Company	Overall Sentiment
Organigram Global	Neutral
Talphera	Positive

Summary

Talphera beats Organigram Global on 9 of the 14 factors compared between the two stocks.

Get Talphera News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLPH vs. The Competition

Export

Metric	Talphera	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$40.22M	$2.96B	$6.49B	$11.99B
Dividend Yield	N/A	1.70%	2.67%	5.57%
P/E Ratio	-2.73	17.68	23.68	23.74
Price / Sales	1,464.96	286.81	507.33	108.39
Price / Cash	N/A	56.17	26.99	37.25
Price / Book	2.29	3.83	10.28	6.78
Net Income	-$14.29M	$75.85M	$3.57B	$337.51M
7 Day Performance	9.22%	-2.00%	0.28%	-2.34%
1 Month Performance	-6.30%	-5.85%	3.27%	1.88%
1 Year Performance	64.40%	14.03%	22.22%	25.55%

Talphera Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLPH Talphera	4.0135 of 5 stars	$0.85 +9.3%	$3.00 +254.3%	+66.0%	$40.22M	$30K	N/A	19	Analyst Forecast Analyst Revision Gap Up High Trading Volume
SPRO Spero Therapeutics	1.0193 of 5 stars	$2.83 flat	N/A	+9.6%	$163.86M	$66.80M	11.79	150	Positive News
PLX Protalix BioTherapeutics	2.5646 of 5 stars	$2.00 -3.2%	$12.00 +501.5%	+24.1%	$160.74M	$76.38M	N/A	200
MOLN Molecular Partners	3.2467 of 5 stars	$3.92 -0.8%	$8.38 +113.6%	+13.6%	$159.48M	$5.65M	N/A	180
ORMP Oramed Pharmaceuticals	1.749 of 5 stars	$3.60 -7.5%	N/A	+64.0%	$159.20M	$2M	1.39	10	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLPH) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Talphera (TLPH) Competitors

TLPH vs. SPRO, PLX, MOLN, ORMP, and OGI

How does Talphera compare to Spero Therapeutics?

Summary

How does Talphera compare to Protalix BioTherapeutics?

Summary

How does Talphera compare to Molecular Partners?

Summary

How does Talphera compare to Oramed Pharmaceuticals?

Summary

How does Talphera compare to Organigram Global?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH vs. The Competition

Talphera Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Talphera (TLPH) Competitors

TLPH vs. SPRO, PLX, MOLN, ORMP, and OGI

How does Talphera compare to Spero Therapeutics?

Which has more volatility and risk, TLPH or SPRO?

Does the media prefer TLPH or SPRO?

Do insiders and institutionals believe in TLPH or SPRO?

Is TLPH or SPRO more profitable?

Do analysts recommend TLPH or SPRO?

Which has higher valuation & earnings, TLPH or SPRO?

Summary

How does Talphera compare to Protalix BioTherapeutics?

Which has more volatility and risk, TLPH or PLX?

Is TLPH or PLX more profitable?

Which has higher valuation and earnings, TLPH or PLX?

Does the media prefer TLPH or PLX?

Do analysts prefer TLPH or PLX?

Do institutionals & insiders believe in TLPH or PLX?

Summary

How does Talphera compare to Molecular Partners?

Which has more risk & volatility, TLPH or MOLN?

Does the media prefer TLPH or MOLN?

Do analysts prefer TLPH or MOLN?

Which has preferable valuation & earnings, TLPH or MOLN?

Do institutionals and insiders believe in TLPH or MOLN?

Is TLPH or MOLN more profitable?

Summary

How does Talphera compare to Oramed Pharmaceuticals?

Does the media refer more to TLPH or ORMP?

Which has stronger earnings and valuation, TLPH or ORMP?

Which has more risk & volatility, TLPH or ORMP?

Do institutionals & insiders have more ownership in TLPH or ORMP?

Is TLPH or ORMP more profitable?

Do analysts recommend TLPH or ORMP?

Summary

How does Talphera compare to Organigram Global?

Do institutionals and insiders have more ownership in OGI or TLPH?

Which has stronger earnings and valuation, OGI or TLPH?

Which has more risk and volatility, OGI or TLPH?

Is OGI or TLPH more profitable?

Do analysts recommend OGI or TLPH?

Does the media favor OGI or TLPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH vs. The Competition

Talphera Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools